Granules India Ltd. (GRANULES) fundamentals
Granules India Ltd. is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as GRANULES (ISIN INE101D01020). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Granules India Ltd. does
Granules India Limited is an India-based pharmaceutical manufacturing company. The Company operates through its pharmaceutical products segment. Its geographical segments include within India and outside India. The Company has a presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It produces and supplies Paracetamol, Metformin, Guaifenesin, and Methocarbamol APIs. It has over 10 manufacturing facilities, approximately eight of which are located in India and two in the United States. The Company sells its products in global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific, and India. Its subsidiaries include Granules USA Inc and Granules Europe Limited. It also owns Senn Chemicals AG, a contract development and manufacturing organization (CDMO) specializing in peptide development and manufacturing.
Valuation and market data
| Last close | ₹822.00 |
|---|---|
| Market capitalisation | ₹19,988 crore |
| Enterprise value | ₹19,651 crore |
| P/E (TTM) | 33.59 |
| Price to book | 3.93 |
| Price to sales (TTM) | 2.10 |
| Book value per share | ₹209.12 |
| Dividend yield | 21.29% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Mon Jun 20 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹5,386 crore | ₹785 crore | ₹595 crore | 24.47 |
| Mar 2025 | ₹4,495 crore | ₹660 crore | ₹502 crore | 20.69 |
| Mar 2024 | ₹4,511 crore | ₹547 crore | ₹405 crore | 16.73 |
| Mar 2023 | ₹4,526 crore | ₹687 crore | ₹517 crore | 21.05 |
Figures are as reported (consolidated), in ₹ crore.
Shareholding pattern
As of Sep 2026:
| Promoters | 37.4% |
|---|---|
| Foreign institutions (FII) | 20.3% |
| Mutual funds | 4.3% |
| Other domestic institutions | 11.1% |
| Retail and others | 27.0% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.